Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Completed

EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma

Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Unresectable Pancreatic Adenocarcinoma - a Randomised Controlled Trial

Outcome
Finished, no results posted
Phase
No phase (not a drug trial)
Status
Completed
Study type
Interventional
Start
20 December 2018
Ended
16 August 2021
Enrollment
38 participants
Sites
2
Primary outcomes
Change in tumour size as measured on EUS and or CT; Change in serum levels of Ca 19-9
Sponsor type
Academic / other
Results posted
No
Last update
30 August 2021

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a prospective randomised trial in patients with inoperable PDAC.

Detailed description public domain (ClinicalTrials.gov)

The five year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite of the advances in management of cancers in the last few decades. Endobiliary application of radiofrequency ablation (RFA) has been developed in our unit and used in patients with unresectable bile duct and pancreatic head adenocarcinomas presenting with biliary obstruction. Various techniques of EUS-guided tumour ablation have been described, including RF ablation, photodynamic therapy, laser ablation, and ethanol injection. Endoscopic ultrasound guided RFA (EUS-RFA) of the pancreatic head using Habib EUS-RFA catheter through a 19-gauge needle was well tolerated in 5 Yucatan pigs and with minimum amount of pancreatitis .